|

ADI-PEG20 Clinical Trials

4 actively recruiting trials across 1 location

Also known as: Pegargiminase, pegargiminase, pegylated arginine deiminase

Pipeline

Phase 2: 2Phase 3: 2

Top Sponsors

  • Polaris Group3
  • Chang Gung Memorial Hospital1

Indications

  • Liver Disease3
  • Cancer3
  • Liver Cancer2
  • Hepatocellular Carcinoma2
  • Nonalcoholic Steatohepatitis (NASH)1

Other3 trials

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
Phase 2
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Phase 3
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Phase 2

Phoenix, Arizona1 trial

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Mayo Clinic Arizona

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.